Pandemic Preparedness: Overcoming Challenges In A 2000 Liter Scale Up For Adenovirus-Based Vaccine Manufacturing

The COVID-19 pandemic underscored the importance of large-scale vaccine production for our healthcare infrastructure. To meet the demand for significant quantities within tight timelines, advanced technology with high capacity is essential. IDT Biologika has implemented a pandemic preparedness strategy that showcases the company's readiness for mass-producing viral vector vaccines. Specifically, a robust process for manufacturing Adenovirus (AdV) vectors has been devised and effectively scaled up to a 2000 L stirred tank reactor (STR). Here, the workflow and obstacles that were encountered and successfully overcome during process development are outlined.